British Journal of Cancer - Volume 62, issue 4

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras neque tellus, ornare vel pulvinar luctus, vestibulum malesuada ante. Nullam pellentesque, ipsum vel fermentum tincidunt, velit neque molestie lacus, at iaculis purus mauris in nisl. Nullam vehicula imperdiet auctor. Mauris tempus, leo eget euismod condimentum, erat justo vehicula augue, vitae ornare elit felis nec libero. Etiam et quam sit amet metus dignissim dictum sed vitae purus. Phasellus gravida hendrerit risus vitae euismod. In elementum massa facilisis nulla pulvinar at pharetra leo pellentesque.

Electronic ISSN
1532-1827
Print ISSN
0007-0920

Abstract

Pyrazinamide, the pyrazine analogue of nicotinamide, has been evaluated for its ability to modify the radiation response of hypoxic cells both in vivo and in vitro. Results obtained with three different murine tumour systems EMT6, LLC and SCCVII showed that pyrazinamide at a dose of 0.5 mg g-1 i.

Journal: British Journal of Cancer, vol. 62, no. 4, 1990